With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.5908-62-3,1,1-Dioxo-isothiazolidine,as a common compound, the synthetic route is as follows.
To a stirred solution of 5-{9-fluoro-6-methanesulfonyl-5-[(S)-oxan-4- y l(pheny l)methy 1] -5H-py rido [3,2-b] indol-3 -y 1 } – 1 ,4-dimethy 1- 1H- 1 ,2,3-triazole (25.0 mg 0.0500 mmol) and isothiazolidine-l,l-dione (5.7 mg, 0.0500 mmol) in DMF (0.25 mL) was added t-BuOK (21.0 mg, 0.190 mmol). This mixture was heated at 65 C for 1.5 h and cooled to room temperature. The mixture was then diluted with MeOH and purified via preparative LC/MS with the following conditions: Column: Waters XBridge Phenyl, 19 x 200 mm, 5-mutaueta particles; Mobile Phase A: 5:95 ACN: water with 10 mM NH4OAC; Mobile Phase B: 95:5 ACN: water with 10 mM NH4OAc; Gradient: 15-70% B over 20 min, then a 5-min hold at 100% B; Flow: 20 mL/min. Fractions containing the desired product were combined and dried via centrifugal evaporation to give 2-[3-(dimethyl-lH- l,2,3-triazol-5-yl)-6-methanesulfonyl-5-[(S)-oxan-4-yl(phenyl)methyl]-5H-pyrido[3,2- b]indol-9-yl]- 6,2-thiazolidine-l,l-dione (12.3 mg, 41%). NMR (500MHz, DMSO- de) delta 8.72 (s, IH), 8.38 (d, J=8.4 Hz, IH), 7.88 (s, IH), 7.62 (br d, J=8.4 Hz, 3H), 7.36- 7.30 (m, 2H), 7.27 (br d, J=7.1 Hz, IH), 6.81 (br d, J=10.1 Hz, IH), 4.11 (br d, J=2.0 Hz, 2H), 3.86 (br d, J=9.8 Hz, IH), 3.76 (s, 3H), 3.74 (s, 2H), 3.64 (br d, J=8.8 Hz, IH), 3.57 (br t, J=7.4 Hz, IH), 3.19 (br t, J=12.1 Hz, IH), 2.65-2.57 (m, 2H), 2.54 (s, 3H), 2.07 (s, 3H), 1.95 (br d, J=12.5 Hz, IH), 1.75-1.56 (m, 2H), 0.42 (br d, J=12.1 Hz, IH). LCMS: RT = 1.414 min; (ES): m/z (M+H)+ = 634.95; LCMS: Column: Waters Acquity UPLC BEH C18, 2.1 x 50 mm, 1.7-muiotaeta particles; Mobile Phase A: 5:95 ACN:water with 10 mM NH4OAc; Mobile Phase B: 95:5 ACN:water with 10 mM NH4OAC; Temperature: 50 C; Gradient: 0-100% B over 3 min, then a 0.75-min hold at 100% B; Flow: 1.11 mL/min. HPLC Purity at 220 nm: 100 %
The synthetic route of 5908-62-3 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; BRISTOL-MYERS SQUIBB COMPANY; HAN, Wen-Ching; DEGNAN, Andrew P.; DESKUS, Jeffrey A.; GAVAI, Ashvinikumar V.; GILL, Patrice; SCHMITZ, William D.; STARRETT, John E., Jr.; (193 pag.)WO2016/183115; (2016); A1;,
Thiazolidine – Wikipedia
Thiazolidine – ScienceDirect.com